Rafferty Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Rafferty Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.79M	Sell	110,254 -71,422	-39%	-$1.57M	0.01%	563
2026 Q1	$4.04M	Sell	181,676 -16,587	-8%	-$396K	0.02%	460
2025 Q4	$5.3M	Buy	198,263 +3,232	+2%	+$77.2K	0.02%	420
2025 Q3	$4.16M	Buy	195,031 +69,294	+55%	+$1.64M	0.01%	467
2025 Q2	$2.71M	Sell	125,737 -74,552	-37%	-$1.39M	0.01%	536
2025 Q1	$3.33M	Buy	200,289 +50,055	+33%	+$909K	0.01%	453
2024 Q4	$2.76M	Sell	150,234 -135,507	-47%	-$2.19M	0.01%	551
2024 Q3	$4.39M	Sell	285,741 -19,338	-6%	-$323K	0.02%	448
2024 Q2	$4.96M	Sell	305,079 -86,146	-22%	-$1.39M	0.02%	417
2024 Q1	$7.23M	Sell	391,225 -36,705	-9%	-$909K	0.03%	374
2023 Q4	$13.4M	Buy	427,930 +91,317	+27%	+$2.18M	0.06%	211
2023 Q3	$7.02M	Buy	336,613 +584	+0.2%	+$15.9K	0.04%	322
2023 Q2	$8.05M	Buy	336,029 +3,668	+1%	+$81.5K	0.05%	271
2023 Q1	$6.26M	Sell	332,361 -224,320	-40%	-$4.27M	0.04%	332
2022 Q4	$8.86M	Buy	556,681 +158,005	+40%	+$2.47M	0.07%	217
2022 Q3	$6.52M	Buy	398,676 +175,222	+78%	+$2.84M	0.07%	248
2022 Q2	$3.15M	Sell	223,454 -7,229	-3%	-$135K	0.03%	379
2022 Q1	$5.59M	Sell	230,683 -6,215	-3%	-$150K	0.03%	360
2021 Q4	$5.53M	Buy	236,898 +43,230	+22%	+$869K	0.03%	352
2021 Q3	$3.22M	Buy	193,668 +98,537	+104%	+$1.9M	0.02%	437
2021 Q2	$2.32M	Sell	95,131 -28,091	-23%	-$634K	0.01%	647
2021 Q1	$3.18M	Buy	123,222 +105,036	+578%	+$4.62M	0.02%	453
2020 Q4	$972K	Sell	18,186 -35,995	-66%	-$1.79M	0.01%	503
2020 Q3	$2.23M	Buy	54,181 +33,346	+160%	+$1.44M	0.03%	379
2020 Q2	$1.01M	Buy	20,835 +10,427	+100%	+$501K	0.01%	538
2020 Q1	$440K	Sell	10,408 -78,071	-88%	-$3.22M	0.02%	361
2019 Q4	$3.79M	Sell	88,479 -35,204	-28%	-$1.53M	0.06%	180
2019 Q3	$4.45M	Sell	123,683 -77,572	-39%	-$2.35M	0.07%	165
2019 Q2	$5.38M	Buy	201,255 +8,735	+5%	+$223K	0.09%	146
2019 Q1	$5.17M	Buy	+192,520	New	+$4.5M	0.08%	133

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rafferty Asset Management's ACAD Position: Q2 2026 in Review

Rafferty Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 39% in Q2 2026, selling an estimated $1.57M and leaving 110,254 shares worth $2.79M. The position accounts for 0.01% of the portfolio, ranked #563.

Rafferty Asset Management first reported a position in ACAD in Q1 2019 and has held it in 30 quarters since. The position peaked at $13.4M in Q4 2023. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Rafferty Asset Management held 110,254 shares of Acadia Pharmaceuticals worth $2.79M as of Q2 2026.
Rafferty Asset Management sold 71,422 Acadia Pharmaceuticals shares in Q2 2026, an estimated $1.57M.
Acadia Pharmaceuticals made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #563 holding.
Rafferty Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2019 and has held it in 30 quarters since.
Rafferty Asset Management's Acadia Pharmaceuticals position peaked at $13.4M in Q4 2023.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.